Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

313 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes.
Saliby RM, Labaki C, Jammihal TR, Xie W, Sun M, Shah V, Saad E, Kane MH, Kashima S, Sadak K, El Zarif T, Poduval D, Motzer RJ, Powles T, Rini BI, Albiges L, Pal SK, McGregor BA, McKay RR, Signoretti S, Van Allen EM, Shukla SA, Choueiri TK, Braun DA. Saliby RM, et al. Among authors: albiges l. Cancer Cell. 2024 May 13;42(5):732-735. doi: 10.1016/j.ccell.2024.03.002. Epub 2024 Apr 4. Cancer Cell. 2024. PMID: 38579722
PD-L1 expression in nonclear-cell renal cell carcinoma.
Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L, Bellmunt J, Song J, Carvo I, Lampron M, Stanton ML, Hodi FS, McDermott DF, Atkins MB, Freeman GJ, Hirsch MS, Signoretti S. Choueiri TK, et al. Among authors: albiges l. Ann Oncol. 2014 Nov;25(11):2178-2184. doi: 10.1093/annonc/mdu445. Epub 2014 Sep 5. Ann Oncol. 2014. PMID: 25193987 Free PMC article.
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.
Callea M, Albiges L, Gupta M, Cheng SC, Genega EM, Fay AP, Song J, Carvo I, Bhatt RS, Atkins MB, Hodi FS, Choueiri TK, McDermott DF, Freeman GJ, Signoretti S. Callea M, et al. Among authors: albiges l. Cancer Immunol Res. 2015 Oct;3(10):1158-64. doi: 10.1158/2326-6066.CIR-15-0043. Epub 2015 May 26. Cancer Immunol Res. 2015. PMID: 26014095 Free PMC article.
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kaymakcalan MD, Xie W, Albiges L, North SA, Kollmannsberger CK, Smoragiewicz M, Kroeger N, Wells JC, Rha SY, Lee JL, McKay RR, Fay AP, De Velasco G, Heng DY, Choueiri TK. Kaymakcalan MD, et al. Among authors: albiges l. Cancer. 2016 Feb 1;122(3):411-9. doi: 10.1002/cncr.29773. Epub 2015 Nov 5. Cancer. 2016. PMID: 26540173 Free article.
313 results